HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Aligning With FDA On Cannabinoids, California Lawmakers Move On Lawful Use

Executive Summary

State Senate scheduled to vote on bill on 8 September and Assembly later in week. Floor votes prompted by amendment removing language that banned hemp smokables in the state, replaced by a phase-in approach.

You may also be interested in...



California On Verge On Legalizing CBD-Containing Cosmetics Along With Dietary Supplements, Foods

In January, the California Department of Public Health quietly added cosmetics to the list of products deemed adulterated if they contain cannabidiol or other hemp-derived substances, along with food products and dietary supplements. All that will change if/when Gov. Gavin Newsom signs AB-45.

Schumer Includes Cannabinoid Pathway For Supplements In Cannabis Legalization Draft Bill

Draft bill proposes rules not only on producing and marketing marijuana, but on using in supplements ingredients derived from cannabis plants classified as hemp. Some supplement industry stakeholders see draft as delivering on industry requests but others say it goes too far.

US Senate Appetite For Lawful Use Of Cannabinoids Includes Food On Top Of Supplements

Senate bill introduced on 19 May, unlike a House bill introduced in February, would direct FDA to allow using hemp-derived cannabinoids in food products as well as supplements. However, neither bill includes language on setting a safe daily level that some industry stakeholders argue is needed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel